Abu Dhabi-based investment and holding company, ADQ has entered into a definitive agreement to acquire Birgi Mefar Group (BMG), one of Turkey’s leading producers of sterile injectable products.
As a full-service pharmaceutical contract development and manufacturing organization (CDMO), BMG is a production service provider for sterile injectable products, namely vials and pre-filled syringes used for vaccines.
BMG also produces primary packaging ampoules and vials for other sterile injectables and specializes in the growing demand for drug lyophilization. The company exports to more than 30 countries, including markets across Europe and Asia with more than 50 years of expertise and excellence.
“BMG’s diversified offering and manufacturing capabilities make the company a strategic addition to our growing portfolio as we continue to shape the UAE’s healthcare & life sciences platform. Turkey is an important market for our investments, and BMG brings with it a strong presence throughout the pharmaceutical supply chain, from drug development and manufacturing to packaging and cold chain distribution. With this integrated capability, we believe it can enhance local expertise and build on the UAE’s ability to manufacture and distribute quality health products as the region’s leading pharmaceutical hub.”
This is part of ADQ’s efforts in the UAE to build a completely integrated healthcare and life sciences platform. It will give ADQ access to a rapidly developing market of injectables and high-value treatments like vaccines, as well as a varied customer network spanning from huge multinationals to small and regional companies.
Moreover, the acquisition will enable BMG to join ADQ’s Healthcare and Life Science portfolio that aims to enhance manufacturing, distribution and commercialization capabilities, including the provision of sterile health products and injectable solutions.
Mr. Faik Somer, CEO at BMG, said that “Joining ADQ’s portfolio is an exciting next step in our journey that will elevate our offering and enable us to scale in lucrative markets like the UAE and wider MENA region. For more than 50 years, we have been committed to quality healthcare and with ADQ’s support, we will be in a stronger position to deliver excellence in global contract development and manufacturing of sterile products that will ultimately generate long-term sustainable growth.”
In September 2021, ADQ acquired Acino, a Swiss-based pharmaceutical manufacturer with a presence in more than 90 countries, marking its largest deal within the healthcare and pharmaceuticals portfolio.